近期，赛诺菲与梯瓦制药联合发布了在研单抗Duvakitug在针对溃疡性结肠炎（UC）和克罗恩病（CD）患者的2b期临床试验中取得的显著成果。数据显示，这种潜在的“最佳类”疗法在第14周时，让接受治疗的患者显著减轻症状，显示出其在未来治疗炎症性肠病中的巨大潜力。

TL1A is encoded by TNFSF15 and is produced by endothelial cells. 5 Expression of TL1A can be induced in endothelial cells and chondrocytes under the influence of the inflammatory cytokines TNF and ...

Ulcerative colitis (UC) is a chronic disease that causes inflammation in the large intestine, affecting between 600,000 and ...

today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) ...

TL1A – or tumour necrosis factor-like ligand ... In RELIEVE UCCD, 36.2% of UC patients treated with a low dose of duvakitug achieved clinical remission by week 14, compared to 20.45% of a ...

It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD. Its successful immunology drug Rinvoq is approved for treating both UC and CD ...

TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

Elsewhere in the market of UC, Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A, duvakitug, met its ...

a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease ...

TL1A is secreted by a number of cells ... So is that the cost of admission to getting a high level of usage you think in UC given the competitive intensity of the space? Thanks.